Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- NHS rolls out fast tracked immunotherapy for advanced endometrial canceron March 5, 2024 at 1:02 am
Immunotherapy dostarlimab (Jemperli) will be available on the NHS for patients with advanced primary or recurrent endometrial cancer after trial results showed that it can slow the spread of the ...
- Unlocking Cures: Expert Shares Anecdotes On Immunotherapy, Vaccines, And Managing Rare Diseases Through Techon March 4, 2024 at 3:04 pm
To understand how the fields of pharmacology, immunology, and vaccine development have improved over the years, and interesting facts about rare diseases, ABP Live spoke to an AstraZenaca scientist.
- Global Healthy Living Foundation Announces irAE Consortium to Address Immune-Related Adverse Events in Cancer Immunotherapy Patientson March 4, 2024 at 7:53 am
This initiative aims to address the unmet needs of cancer patients who experience adverse reactions to immunotherapy, a novel treatment approach. The consortium is committed to elevating the quality ...
- Breakthrough immunotherapy targets non-cancer cells to prevent breast cancer spreadon March 4, 2024 at 2:28 am
A new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumors, according to new research funded by Breast Cancer Now. The discovery, ...
- Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Canceron March 3, 2024 at 4:00 pm
Further correlative analysis of this cohort is ongoing." "This represents a small first step toward a more personalized approach to treatment with immunotherapy," he added. "This abstract is ...
- Microbiome Helps Identify Who Benefits from Combination Immunotherapyon March 2, 2024 at 7:20 pm
Specific strains of bacteria have been linked with a positive response to combination immunotherapy in the largest study of its kind.
- Microbial signatures linked to immunotherapy response across cancerson March 1, 2024 at 7:47 pm
The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.
- New microbiome insights could help boost immunotherapy for a range of rare cancerson February 29, 2024 at 4:00 pm
The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma. Researchers ...
- Microbiome Signature Predicts Success of Immunotherapy Across Multiple Cancerson February 29, 2024 at 4:00 pm
Researchers from the Wellcome Sanger Institute, the Olivia Newton-John Cancer Research Institute in Australia, and collaborators, have identified specific strains of bacteria that are linked with a ...
- Targeted immunotherapy could lead to pioneering treatment for breast canceron February 29, 2024 at 10:34 am
A new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumors, according to new research.
via Bing News